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Summary and time interval to diagnosis. It is the most frequently
diagnosed noncutaneous cancer and the second most
Linkage of a putative prostate cancer–susceptibility lo-
common cause of cancer-related deaths in American
cus (HPC1) to chromosome 1q24-25 has recently been
men (Parker et al. 1997). Several studies have demon-
reported. Conﬁrmation of this linkage in independent
strated familial clustering of prostate cancer, suggesting
data sets is essential because of the complex nature of
a heritable form of the disease (Steinberg et al. 1990;
this disease. Here we report the results of a linkage anal-
Carter et al. 1992, 1993). Segregation analysis based on
ysis using 10 polymorphic markers spanning Ç37 cM
data from 691 prostate cancer probands suggested that
in the region of the putative HPC1 locus in 49 high-risk
inherited forms of this disease are best explained by a
prostate cancer families. Data were analyzed by use of
rare, highly penetrant, autosomal dominant allele (Car-
two parametric models and a nonparametric method.
ter et al. 1992). This analysis also predicted that the
For the parametric LOD-score method, the ﬁrst model
inheritance of this allele accounts for Ç43% of early-
was identical to the original report by Smith and co-
onset prostate cancers, deﬁned as diagnosis at age £55
workers (‘‘Hopkins’’), and the second was based on a years, and for Ç9% of prostate cancers diagnosed by
segregation analysis previously reported by Carter and age 85 years. Although inherited factors appear to ac-
coworkers (‘‘Seattle’’). In both cases, our results do not count for only a small subset of all prostate cancers,
conﬁrm the linkage reported for this region. Calculated the identiﬁcation of such a disease gene(s) is considered
LOD scores from the two-point analysis for each marker crucial to an understanding of the molecular and cellular
were highly negative at small recombination fractions. mechanisms that contribute to the development of pros-
Multipoint LOD scores for this linkage group were also tate cancer.
highly negative. Additionally, we were unable to demon- The genetic etiology responsible for the neoplastic
strate heterogeneity within the data set, using HOMOG. transformation of normal prostate cells remains largely
Although these data do not formally exclude linkage of unknown, although research has identiﬁed several genes
a prostate cancer–susceptibility locus at HPC1, it is involved in the progression of prostate tumors; these
likely that other prostate cancer–susceptibility loci play include the MAX-interacting protein 1 (MXI1) on
a more critical role in the families that we studied. 10q25 (Eagle et al. 1995), a suppressor of the metastasis
gene (KAI1) on 11p11.2 (Dong et al. 1996; Ichikawa
et al. 1996), the androgen-receptor locus on Xq11-12Introduction
(Irvine et al. 1995), and a cell-cell adhesion system (E-
Prostate cancer is a complex disease marked by varying cadherin/a-catenin) critical for tumor metastasis (Um-
rates of progression, response to therapies, age at onset, bas et al. 1992; Morton et al. 1993). Mutations in tu-
mor-suppressor genes shown to be important in other
cancers, such as p53 and Rb1, can be detected in a
Received February 10, 1997; accepted for publication May 30, proportion of advanced-stage prostate cancers
1997. (Bookstein et al. 1993; Massenkeil et al. 1994); never-
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eostrand@fhcrc.org al. 1996). Similarly, loss-of-heterozygosity studies have
*These authors contributed equally to the study identiﬁed several regions that may contain unidentiﬁed
†Present afﬁliation: Department of Oncological Sciences, University tumor-suppressor genes, including 7q, 8p, 10p, 10q,
of Utah, Salt Lake City.
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1994; Kagan et al. 1995; Macoska et al. 1995; Bova et DNA (50 ng), primers (0.2 mM each), 50 mM KCl, 10
mM Tris, 1–2.5 mM MgCl2, 0.2 mM dNTPs, and 0.5al. 1996; Williams et al. 1996); but, as yet, there is no
evidence that prostate cancer–susceptibility genes are in mM dATP-IRD40 or a32P-dCTP. The samples were cy-
cled 35 times at 94C for 15 s, 50C–58C for 15 s, andany of these candidate regions. Thus, known tumor-
suppressor genes do not account for the majority of 72C for 15 s. Markers were optimized for both their
annealing temperature (50C–58C) andMgCl2 concen-familial prostate cancer, and the identiﬁcation of suscep-
tibility loci remains a major goal of prostate cancer re- tration (1.0–2.5 mM). Products were labeled during
strand synthesis, with either an infrared dye (dATP-search.
Smith et al. (1996) recently screened 91 North Ameri- IRD40; Boehringer Mannheim) or a32P-labeled dCTP
(Redivue; Amersham). Products were resolved on dena-can and Swedish families, with microsatellite markers.
Two-point analysis of 66 North American families turing polyacrylamide gels, with the dye-labeled prod-
ucts detected by use of a Li-CorModel 4000S automatedfound suggestive linkage (LOD score 2.75) with
D1S218, a marker in chromosome 1q24-25. Analysis of infrared DNA sequencer (Li-Cor), and the genotypes
were determined by use of proprietary in-house genotyp-an additional 25 families and markers narrowed the
region of linkage to an interval of Ç15 cM deﬁned by ing software (SAGA). All radioactive gels were indepen-
dently scored by at least two people. Estimated geno-markers D1S2883 to D1S422. An admixture test for
homogeneity suggested an estimated 34% of the families typic error rates were 0.22%.
studied by Smith et al. were linked to this region. Given
Linkage Analysisboth the complex nature of this disease and the potential
importance of this ﬁnding, we have attempted to verify The parametric-LOD-method linkage analyses used
two models for the inheritance of prostate cancer inthis result in a similar group of families.
these high-risk families (table 1). The ﬁrst model
(‘‘Hopkins’’) was identical to the model used by SmithSubjects and Methods
et al. (1996) in their report of linkage to chromosome
Ascertainment of Prostate Cancer Families 1. This was used to ensure that result differences were
not secondary to model differences. This model wasThe Prostate Cancer Genetic Research Study
autosomal dominant with a risk-allele frequency of(PROGRESS) was initiated in July 1995 for the purpose
.003 (q) and three liability classes (table 1). All affectedof identifying familial clusters of prostate cancer and,
men were in the ﬁrst liability class, regardless of age,ultimately, inherited susceptibility genes. National ad-
and the class had a phenocopy rate of .001 and a pene-vertising, media events, and mailings to support groups
trance of 1.0 for carriers of the disease allele. Alland urologists were used to recruit families into the
women and unaffected men õ75 years of age werestudy. A toll-free number (800-777-3035) was estab-
grouped together in the second liability class, whereaslished to screen potential participants for their suitabil-
unaffected men §75 years of age were placed in theity. For participation, families were selected on the ba-
third liability class (table 1). The second model (‘‘Seat-sis of the number of ﬁrst-degree relatives diagnosed
tle’’) closely followed the results of Carter et al. (1993),with prostate cancer, the age at diagnosis of the affect-
by using age-dependent penetrance values for individu-eds, and the number of living affecteds from whom
als ú50 years of age. This model was also autosomalblood samples could be obtained. The study and its
dominant with a risk-allele frequency of .003 (Carterconsent and medical record–release forms were ap-
et al. 1992). Unlike the Hopkins model, there wereproved by the institutional review board of the Fred
seven liability classes (table 1). Men õ30 years of ageHutchinson Cancer Research Center. All consent and
and women were considered to have zero risk of cur-medical record–release forms were signed and returned
rently having prostate cancer.to PROGRESS. Affected members of selected families
FASTLINK version 3.0P (Cottingham et al. 1993)were asked to give medical and family-history informa-
and LINKAGE version 5.1 (Lathrop et al. 1984) weretion and to donate a blood sample. Medical record
used for the two-point linkage analysis. Multipointconﬁrmation of diagnosis was sought. Selected unaf-
parametric and nonparametric linkage (NPL) analysesfected family members expected to be informative for
used GENEHUNTER version 1.1 (Kruglyak et al.linkage were then recruited.
1996). In addition, nonparametric two-point analyses
DNA Isolation and Genotyping used the nonparametric option of the ANALYZE link-
age computer package by Joseph Terwilliger. Allele fre-Genomic DNAs were isolated from previously frozen
buffy coats by standard methods. Genomic DNA from quencies were determined from the data set by use of
downfreq from ANALYZE. An admixture test for het-each individual was genotyped by PCR ampliﬁcation of
10 microsatellite markers spanning the putative HPC1 erogeneity in the data set was performed by use of
HOMOG (Ott 1991).locus on 1q24-25. Each reaction contained genomic
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Table 1
Parametric Models of Inheritance That Were Evaluated in Present Study
PENETRANCE
Homozygous Normal Heterozygous Homozygous Disease
Hopkins:a
1 Affected men Affected .001 1.0 1.0
2 Women Unknown .5 .5 .5
2 Unaffected men õ75 years of age Unknown .5 .5 .5
3 Unaffected men §75 years of age Unaffected .16 .63 .63
Seattle:
1 Women Unaffected .0 .0 .0
1 Men õ30 years of age Unaffected .0 .0 .0
2 Men 30–39 years of age Unaffected or affected .001 .0045 .0045
3 Men 40–49 years of age Unaffected or affected .001 .01 .01
4 Men 50–59 years of age Unaffected or affected .005 .05 .05
5 Men 60–69 years of age Unaffected or affected .01 .37 .37
6 Men 70–79 years of age Unaffected or affected .05 .76 .76
7 Men ú79 years of age Unaffected or affected .05 .88 .88
a Model speciﬁcations kindly provided by Jianfeng Xu.
Table 2
Two-Point LOD Scores for 10 Chromosome 1q24-25 Markers, under the Seattle Model and under the Hopkins Model,
for 46 Caucasian Families
LOD SCORE AT u Å
MODEL AND LOCUS .00 .05 .10 .20 .30 .40 Zmaxa Zmax (a, u)b
Seattle:
D1S1677 09.28 05.46 03.37 01.24 0.38 0.07 .0 () .0 (1.0, )
D1S1589 08.07 04.78 02.95 01.05 0.29 0.04 .0 () .0 (1.0, )
D1S2883 08.32 04.49 02.59 0.81 0.16 0.01 .001 (.46) .001 (1.0, .46)
D1S212 09.77 05.42 03.22 01.08 0.26 0.03 .0 () .0 (1.0, )
D1S2818 06.20 03.53 02.22 0.89 0.31 0.06 .0 () .0 (1.0, )
D1S2127 08.43 04.13 02.18 0.44 .06 .06 .088 (.34) .208 (.13, .0)
D1S191 06.19 02.99 01.41 0.07 .2 .09 .194 (.30) .194 (1.0, .3)
D1S518 07.54 03.73 01.83 0.19 .18 .08 .180 (.32) .180 (.93, .3)
D1S422 02.16 0.56 .11 .49 .34 .11 .484 (.20) .492 (.53, .10)
D1S1660 08.94 04.44 02.33 0.51 0.02 .03 .036 (.36) .036 (1.0, .36)
Hopkins:
D1S1677 022.63 08.62 04.77 01.55 0.41 0.05 .0 () .0 (1.0, )
D1S1589 018.59 07.62 04.32 01.41 0.35 0.04 .0 () .0 (1.0, )
D1S2883 020.86 07.61 03.78 0.77 .04 .07 .089 (.36) .089 (1.0, .36)
D1S212 013.58 04.14 01.60 .16 .37 .15 .388 (.28) .388 (1.0, .28)
D1S2818 013.71 05.32 03.05 01.12 0.36 0.07 .0 () .0 (1.0, )
D1S2127 019.84 07.19 03.72 0.95 0.1 .03 .027 (.40) .174 (.10, .0)
D1S191 018.66 05.88 02.76 0.42 .11 .08 .133 (.34) .159 (.12, .0)
D1S518 022.26 08.33 04.24 0.93 0.02 .06 .073 (.36) .073 (.95, .36)
D1S422 013.35 03.08 01.02 .22 .31 .11 .332 (.26) .415 (.23, .0)
D1S1660 025.11 08.62 04.33 01.06 0.15 .01 .009 (.42) .009 (1.0, .42)
a Homogeneity is assumed.
b Heterogeneity is assumed.
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Results
The 49 families included in this analysis had an aver-
age of 4.4 men affected with prostate cancer (range 3–
9) and an average age at diagnosis of 65.9 years (range
39–94 years). The average number of living affected
men genotyped per family was 3.5, with an average age
at diagnosis of 64.9 years. A total of 364 individuals,
including 169 affected men, were genotyped. Medical
records were obtained for 165 (98%) of these affected
men. In every case the diagnosis was conﬁrmed. Forty-
six of the 49 families were of Caucasian descent.
LOD scores from the two-point parametric analysis
using both models of inheritance of prostate cancer for
the Caucasian families in this study are given in table 2.
Both the Hopkins model and the Seattle model gave
strong evidence against linkage, for nearly all markers.
The largest positive LOD score for the Seattle model is
0.484 at recombination fraction (u) Å .2, with D1S422,
whereas that for the Hopkins model is 0.388 at u Å .28,
with D1S212. Using an admixture test (HOMOG), we
were unable to ﬁnd signiﬁcant evidence of locus hetero-
geneity in the data set. If heterogeneity is assumed, the
largest LOD score obtained under the Seattle model is
0.492 at u Å .1, with an estimate of .53 (1.0 Å homoge-
neity), whereas that for the Hopkins model is 0.415 at
uÅ .0, with an estimate of .23 for D1S422. An examina-
tion of each family showed no convincing evidence of
linkage to these chromosome 1q markers.
Stratiﬁcation of the dataset, by age at diagnosis, into
‘‘early’’- and ‘‘late’’-onset families did not yield signiﬁ-
cant evidence of linkage. Families were considered to
have an early onset if their mean age of diagnosis was
65 years of age, whereas families whose mean age at
diagnosis was ú65 years were considered to have a
late onset. Our dataset contained 18 Caucasian families
Figure 1 Plot of LOD and NPL scores from the multipointhaving an early onset and 28 families having a late
analysis by GENEHUNTER (Kruglyak et al. 1996). A, Plot of LOD-
onset. Under the Seattle model, the LOD scores derived score values obtained by the Seattle model. B, Plot of LOD-score
for the early-onset families were generally highly nega- values obtained by the Hopkins model. C, Plot of NPL-score values
for this region of chromosome 1. The relative position and markertive at small u’s, with maximum LOD score (Zmax) of
name are given on the x-axis.0.0 at u Å  for all markers tested. The Hopkins model
also gave negative LOD scores at small u’s with Zmax
also of 0.0 at u Å  for all markers. Similarly, under
the Seattle model, the LOD scores for the late-onset multipoint LOD and NPL scores across this region of
families were again highly negative, with Zmax Å 0.708 chromosome 1q24-25, under both models, is shown in
at u Å .16, for marker D1S422. However, the Hopkins ﬁgure 1. As in the two-point analysis, there is no signiﬁ-
model did give small positive LOD scores, with Zmax cant evidence for linkage of a prostate cancer–suscepti-
Å 1.09 (12.6:1 likelihood ratio) at u Å .18, for marker bility locus to this region.
D1S212. The results for single Japanese, Latino, and Native-
The parametric analysis relies on having an approxi- American pedigrees in our data set do not appear sig-
mately correct model deﬁned for the mode of inheri- niﬁcantly different from those for the Caucasian fami-
tance. To avoid any risk, secondary to model misspeci- lies. The Japanese and Latino families generally yield
ﬁcation, of falsely rejecting linkage, we performed a low negative LOD scores, under either model. The Na-
nonparametric multipoint analysis, using the GENE- tive-American pedigree gave negative LOD scores under
both the Seattle model and the Hopkins model; however,HUNTER program (Kruglyak et al. 1996). A plot of the
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this pedigree did have two loci with LOD scores of 1.12 tiny. An example of conﬂicting reports was the linkage
of chromosome 21 to familial Alzheimer disease (FAD;(D1S2883) and 1.36 (D1S212), at u Å .0, under the
Hopkins model. St. George-Hyslop et al. 1987) and the subsequent re-
port of the absence of that linkage (Schellenberg et al.
1988). The families found not to be linked to chromo-Discussion
some 21 were later found to show linkage to a more
We found no evidence for linkage of prostate cancer common FAD locus, on chromosome 14 (Schellenberg
to 1q24-25, using three models. Given the similarities et al. 1992), whereas the chromosome 21 locus has been
(table 3) between our data set and that of Smith et al. found to be linked to a small portion of FAD.
(1996), our results are surprising. The 49 families ana- Third, the lack of agreement between our results and
lyzed here are expected to be typical of high-risk prostate those of Smith and coworkers may also reﬂect study-
cancer families. All of the families that we studied have population differences in the presence of locus heteroge-
three or more affected ﬁrst-degree relatives; 21 (42.8%) neity. Despite the obvious similarities between the data
of the 49 families have ﬁve or more affected individuals. sets, some differences can be shown to exist. The data
In addition, 14 families reported disease in two genera- set of Smith and coworkers contained two African
tions. Eleven families meet two critical criteria: having American families that contributed approximately one-
an average age at diagnosis of õ65 years and disease in half of the LOD score for the North American pedigrees
at least two generations. studied, whereas our data contained no African Ameri-
Conﬂicting evidence regarding linkage to a chromo- can families. Differences in prostate cancer morbidity
somal region is not unexpected in common diseases and and mortality have been reported between Caucasians
may be explained by one of the following reasons. First, and African Americans (Walker et al. 1995). Other,
it may represent a false-positive or false-negative linkage more subtle differences are likely to exist as well.
result, or it may represent sample differences in the pres- Finally, given our signiﬁcant evidence against linkage,
ence of locus heterogeneity. In the absence of a biologi- we must consider the hypothesis that either the linkage
cally plausible candidate gene or alternative region of to 1q24-25 is spurious or the reported proportion of
linkage, disputed linkages may be resolved either by linked families (34%) is an overestimate. Whereas the
evaluation of further families or by extension of the report of linkage by Smith and coworkers is supported
families originally reported to be linked. The evaluation by their parametric and nonparametric analyses, the esti-
of further families should improve the estimate of the mated proportion of families with linkage (a), .34, is
proportion of families linked to the reported locus. model dependent. The Hopkins model is unusual and
Second, in the presence of locus heterogeneity, it may deviates from the segregation analysis performed by
be difﬁcult to replicate a linkage that is correct but that Carter et al. (1992, 1993). The segregation data of Car-
represents an infrequent locus. This is especially true ter et al. suggest that the penetrances of prostate cancer
when the families studied by various groups differ in loci are age dependent. This is largely unaccounted for
some way. In that case, the best method to show that in the Hopkins model. Instead, unaffected men õ75
the original linkage was correct is to extend the original years of age are considered to have an unknown diagno-
pedigrees. A true linkage will result in an improved LOD sis, and unaffected men ú75 years of age are grouped
separately (table 1). Furthermore, all affected men arescore, and a false result should not withstand the scru-
Table 3
Comparison of Prostate Cancer Families
Smith et al. (1996) Present Study
Average age (range) at diagnosis, of all affected 64.9 years (39–85 years) 65.9 years (39–94 years)
Average age (range) at diagnosis, if genotyped NA 64.9 years (51–82 years)
Percentage of genotyped affected õ55 years of age 10 9
Average number (range) of affected per family 4.9 (3–15) 4.4 (3–9)
Average number (range) of genotyped affected per family 3.7 (2–11) 3.5 (2–7)
Number of families with:
Two affected sibs NA 5
Three affected sibs NA 28
Four affected sibs NA 15
Five affected sibs NA 1
a NA Å not available.
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Bova GS, Carter BS, Bussemakers MJ, Emi M, Fujiwara Y,assumed to have a very low probability (.001) of being
Kyprianou N, Jacobs SC, et al (1993) Homozygous deletionsporadic cases.
and frequent allelic loss of chromosome 8p22 loci in humanWe were unable to detect any evidence of locus het-
prostate cancer. Cancer Res 53:3869–3873erogeneity in our data set, using an admixture test, under
Bova GS, MacGrogan D, Levy A, Pin SS, Bookstein R, Isaacseither the Hopkins model or the Seattle model, although
WB (1996) Physical mapping of chromosome 8p22 markers
a small fraction of linked pedigrees might have been and their homozygous deletion in a metastatic prostate can-
undetectable. The number of informative families re- cer. Genomics 35:46–54
quired for detection of heterogeneity increases dramati- Brooks JD, Bova GS, Ewing CM, Piantadosi S, Carter BS,
cally at small values of a. The families analyzed here Robinson JC, Epstein JI, et al (1996) An uncertain role for
could be reasonably expected to allow detection of het- p53 gene alterations in human prostate cancers. Cancer Res
56:3814–3822erogeneity at a minimum value of .21–.28 (Cavalli-
Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PCSforza and King 1986). We observed a subset of families
(1992) Mendelian inheritance of familial prostate cancer.in which all affected individuals share haplotypes. How-
Proc Natl Acad Sci USA 89:3367–3371ever, the proportion of families observed did not differ
Carter BS, Bova GS, Beaty TH, Steinberg GD, Childs B, Isaacssigniﬁcantly from that expected under random chance.
WB, Walsh PC (1993) Hereditary prostate cancer: epidemi-One possible explanation for an overestimate of a by
ologic and clinical features. J Urol 150:797–802
Smith et al. is that the model presented was the best Carter BS, Ewing CM, Ward WS, Treiger BF, Aalders TW,
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It is likely that multiple groups will comment on the Cavalli-Sforza LL, King MC (1986) Detecting linkage for ge-
netically heterogeneous diseases and detecting heterogeneityfraction of pedigrees possibly linked to chromosome
with linkage data. Am J Hum Genet 38:599–6161q24-25 and that a better estimate of the proportion of
Cottingham RW Jr, Idury RM, Scha¨ffer AA (1993) Fasterfamilies with prostate cancer linked to this region will
sequential genetic linkage computations. Am J Hum Genetbe derived from the evaluation of larger pools of fami-
53:252–263lies. We believe that this estimate is likely to be signiﬁ-
Dong JT, Suzuki H, Pin SS, Bova GS, Schalken JA, Isaacscantly õ34%. It is clear that multiple loci will be in-
WB, Barrett JC, et al (1996) Down-regulation of the KAI1
volved in the etiology of prostate cancer and that these metastasis suppressor gene during the progression of human
results illustrate the complexity and difﬁculties faced in prostatic cancer infrequently involves gene mutation or al-
the assessment of linkage in a complex disease. lelic loss. Cancer Res 56:4387–4390
Eagle LR, Yin X, Brothman AR, Williams BJ, Atkin NB, Pro-
chownik EV (1995) Mutation of the MXI1 gene in prostateAcknowledgments
cancer. Nat Genet 9:249–255
We are grateful to the participating men and their families, Ichikawa T, Nihei N, Kuramochi H, Kawana Y, Killary AM,
for their generosity and cooperation. We thank Suzanne Kolb, Rinker-Schaeffer CW, Barrett JC, et al (1996) Metastasis
Michael Brannan, and Laurie Hunter for their help with data suppressor genes for prostate cancer. Prostate Suppl 6:31–
collection; Neil Wiegand for technical assistance; and Peter 35
McDonnell for assistance with the pedigree data ﬁles. We also Irvine RA, Yu MC, Ross RK, Coetzee GA (1995) The CAG
thank EllenWisjman,Mary-Claire King, Janet Daling, Kristine and GGC microsatellites of the androgen receptor gene are
Wicklund, and members of the CaP Cure Prostate Cancer in linkage disequilibrium in men with prostate cancer. Can-
Consortium, for their interest and advice. Finally, we thank cer Res 55:1937–1940
Susan Neuhausen and Lisa Cannon-Albright, for their discus- Kagan J, Stein J, Babaian RJ, Joe YS, Pisters LL, Glassman
sion of unpublished results. We would also like to thank Russ AB, von Eschenbach AC, et al (1995) Homozygous deletions
Welti, for his efforts in genotyping-software development. This at 8p22 and 8p21 in prostate cancer implicate these regions
work was supported by awards from the CaP CURE Founda- as the sites for candidate tumor suppressor genes. Oncogene
tion to J.L.S., L.H., and E.A.O., by support from the Fred 11:2121–2126
Hutchinson Cancer Research Center, by American Cancer So- Kruglyak L, DalyMJ, Reeve-DalyMP, Lander ES (1996) Para-
ciety Junior Faculty Award JFRA-558 (to E.A.O) and by the metric and nonparametric linkage analysis: a uniﬁed
support of the Markey Molecular Genetics Center (to G.P.J.). multipoint approach. Am J Hum Genet 58:1347–1363
Lathrop GM, Lalouel JM, Julier C, Ott J (1984) Strategies for
multilocus linkage analysis in humans. Proc Natl Acad SciReferences
USA 81:3443–3446
Macoska JA, Trybus TM, Benson PD, Sakr WA, Grignon DJ,Bookstein R (1994) Tumor suppressor genes in prostatic onco-
genesis. J Cell Biochem Suppl 19:217–223 Wojno KD, Pietruk T, et al (1995) Evidence for three tumor
suppressor gene loci on chromosome 8p in human prostateBookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred
DC (1993) p53 is mutated in a subset of advanced-stage cancer. Cancer Res 55:5390–5395
Massenkeil G, Oberhuber H, Hailemariam S, Sulser T, Dienerprostate cancers. Cancer Res 53:3369–3373
/ 9a30$$au16 08-05-97 19:22:15 ajhga UC-AJHG
353McIndoe et al.: Analysis of Prostate Cancer Families, at 1q24-25
PA, Bannwart F, Schafer R, et al (1994) P53 mutations and St George Hyslop PH, Tanzi RE, Polinsky RJ, Haines JL, Nee
L, Watkins PC, Myers RH, et al (1987) The genetic defectloss of heterozygosity on chromosomes 8p, 16q, 17p, and
18q are conﬁned to advanced prostate cancer. Anticancer causing familial Alzheimer’s disease maps on chromosome
21. Science 235:885–890Res 14:2785–2790
Morton RA, Ewing CM, Nagafuchi A, Tsukita S, Isaacs WB Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC
(1990) Family history and the risk of prostate cancer. Pros-(1993) Reduction of E-cadherin levels and deletion of the
alpha-catenin gene in human prostate cancer cells. Cancer tate Suppl 17:337–347
Umbas R, Schalken JA, Aalders TW, Carter BS, Karthaus HF,Res 53:3585–3590
Ott J (1991) Analysis of human genetic linkage, 2d ed. Johns Schaafsma HE, Debruyne FM, et al (1992) Expression of
the cellular adhesion molecule E-cadherin is reduced or ab-Hopkins University Press, Baltimore and London
Parker SL, Tong T, Bolden S, Wingo PA (1997) Cancer statis- sent in high-grade prostate cancer. Cancer Res 52:5104–
5109tics, 1996. CA Cancer J Clin 46:5–27
Schellenberg GD, Bird TD,Wijsman EM,Moore DK, Boehnke Walker B, Figgs LW, Zahm SH (1995) Differences in cancer
incidence, mortality, and survival between African Ameri-M, Bryant EM, Lampe TH, et al (1988) Absence of linkage
of chromosome 21q21 markers to familial Alzheimer’s dis- cans and whites. Environ Health Perspect Suppl 103:275–
281ease. Science 241:1507–1510
Schellenberg GD, Bird TD, Wijsman EM, Orr HT, Anderson Williams BJ, Jones E, Zhu XL, Steele MR, Stephenson RA,
Rohr LR, Brothman AR (1996) Evidence for a tumor sup-L, Nemens E, White JA, et al (1992) Genetic linkage evi-
dence for a familial Alzheimer’s disease locus on chromo- pressor gene distal to BRCA1 in prostate cancer. J Urol 155:
720–725some 14. Science 258:668–671
Smith JR, Freije D, Carpten JD, Gronberg H, Xu J, Isaacs SD, Zenklusen JC, Thompson JC, Troncoso P, Kagan J, Conti CJ
(1994) Loss of heterozygosity in human primary prostateBrownstein MJ, et al (1996) Major susceptibility locus for
prostate cancer on chromosome 1 suggested by a genome- carcinomas: a possible tumor suppressor gene at 7q31.1.
Cancer Res 54:6370–6373wide search. Science 274:1371–1374
/ 9a30$$au16 08-05-97 19:22:15 ajhga UC-AJHG
